A NEW COST-EFFECTIVENESS MODELLING APPROACH IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION

被引：1
|
作者：
McMurray, J. J. [1 ]
Cowie, M. R. [2 ]
Cohen, A. A. [3 ]
Briggs, A. [1 ]
de Pouvourville, G. [4 ]
Taylor, M. [5 ]
Hancock, E. [6 ]
Trueman, D. [6 ]
Mumby-Croft, J. [6 ]
Haroun, R. [7 ]
Deschaseaux, C. [7 ]
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Imperial Coll London, London, England
[3] Hop St Antoine, Paris, France
[4] ESSEC Business Sch, Cergy Pontoise, France
[5] York Hlth Econ Consortium, York, N Yorkshire, England
[6] Abacus Int, Bicester, Oxon, England
[7] Novartis Pharma AG, Basel, Switzerland
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.887
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV118
引用
收藏
页码：A394 / A394
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of sacubitril/valsartan in chronic heart failure with reduced ejection fraction
    Mcmurray, J. J. V.
    Cowie, M. R.
    Briggs, A.
    Taylor, M.
    Hancock, E.
    Trueman, D. David
    Haroun, R.
    Deschaseaux, C.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 : 276 - 276
  • [2] Cost-effectiveness of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Bellows, Brandon K.
    Kazi, Dhruv S.
    [J]. CIRCULATION, 2020, 142
  • [3] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    [J]. JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
  • [4] THE COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN TURKEY
    Sarioz, F.
    Ozdemir, O.
    Direk, S.
    Caglar, P.
    Ar, I
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A616 - A616
  • [5] COST-EFFECTIVENESS ANALYSIS OF SACUBITRIL/VALSARTAN IN CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN SPAIN
    Lacasa, C.
    Obradors, M.
    Figueras, M.
    Perez-Alcantara, F.
    Brosa, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A650 - A650
  • [6] Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction
    Zanfina, Ademi
    Alena, Pfeil Ma
    Elizabeth, Hancock
    David, Trueman
    Rola, Haroun
    Celine, Deschaseaux
    Matthias, Schwenkglenks
    [J]. SWISS MEDICAL WEEKLY, 2017, 147
  • [7] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF CHRONIC SYMPTOMATIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN THE NETHERLANDS
    Kvamme, I
    de Graaf, G.
    Nekerman, S.
    Gijsbers, S.
    Wester, V
    Hoogendoorn, M.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S170 - S170
  • [8] Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction
    McMurray, John J. V.
    Trueman, David
    Hancock, Elizabeth
    Cowie, Martin R.
    Briggs, Andrew
    Taylor, Matthew
    Mumby-Croft, Juliet
    Woodcock, Fionn
    Lacey, Michael
    Haroun, Rola
    Deschaseaux, Celine
    [J]. HEART, 2018, 104 (12) : 1006 - 1013
  • [9] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN HEART FAILURE WITH REDUCED EJECTION FRACTION IN SWEDEN
    Costa-Scharplatz, M.
    Lang, A.
    McMurray, J. J.
    Woodcock, F.
    Haroun, R.
    Johansson, D.
    Lund, L. H.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A650 - A651
  • [10] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
12345